Provided by Tiger Trade Technology Pte. Ltd.

Phathom Pharmaceuticals

6.92
-0.1600-2.26%
Post-market: 6.990.0700+1.01%19:30 EDT
Volume:1.68M
Turnover:11.72M
Market Cap:559.83M
PE:-5.47
High:7.23
Open:7.20
Low:6.82
Close:7.08
52wk High:18.31
52wk Low:6.82
Shares:80.90M
Float Shares:63.93M
Volume Ratio:1.49
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2659
EPS(LYR):-3.0342
ROE:-3489.00%
ROA:-8.80%
PB:-1.63
PE(LYR):-2.28

Loading ...

Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million

THOMSON REUTERS
·
Jul 30

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Jul 30

Phathom Pharma Schedules Second-quarter Earnings Webcast

Reuters
·
Jul 20

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

GlobeNewswire
·
Jul 20

Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 25

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

TIPRANKS
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna

MT Newswires Live
·
Jun 23

Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults

Reuters
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)

THOMSON REUTERS
·
Jun 23

Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

GlobeNewswire
·
Jun 23

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 17

Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 17

Needham pharmaceuticals analysts hold analyst/industry conference call

TIPRANKS
·
May 27

Phathom Pharma to present at Jefferies Global Healthcare Conference

Reuters
·
May 22

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 22

Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting

Reuters
·
May 22

Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026

Reuters
·
May 20

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

GlobeNewswire
·
May 20

Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss

Simply Wall St.
·
May 09